February 16, 2011


Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right

  • Combination will enhance sanofi-aventis’ sustainable growth strategy by expanding its footprint in biotechnology
  • Genzyme to become sanofi-aventis’ global center for excellence in rare diseases and will maintain a sizeable presence in the greater Boston area

 


Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right
  • Combination will enhance sanofi-aventis’ sustainable growth strategy by expanding its footprint in biotechnology
  • Genzyme to become sanofi-aventis’ global center for excellence in rare diseases and will maintain a sizeable presence in the greater Boston area

Paris, France and Cambridge, Massachusetts – February 16, 2011 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Genzyme Corporation (NASDAQ: GENZ) announced today that they have entered into a definitive agreement under which sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion1. In addition to the cash payment, each Genzyme shareholder will receive one Contingent Value Right (CVR) for each share they own, entitling the holder to receive additional cash payments if specified milestones related to Lemtrada™ (alemtuzumab MS) are achieved over time or a milestone related to production volumes in 2011 for Cerezyme® and Fabrazyme® is achieved.